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Based on previous studies, some comorbidities 
influence the morbidity and mortality of COVID-19 
disease1. Among these factors, opportunistic fungal 
infections could have a major impact on the mortality 
of COVID-19 patients2. Two reasons are assumed to 
play important roles in compromising the immune 
system8 of patients during the early stages of COVID-
19 disease. The first one is a significant decrease of 
different cell components, essentially microphages, 
neutrophils, and lymphocytes. The second one is the 
downregulation of tight junction proteins and the 
integrity and barrier function of the epithelium of 
many body organs, such as lung, intestine, and brain 
impairs3. The immune response varies based on the 
anatomical site of infection and the fungal species. 
However, defects in cell-mediated immunity and 
breakdown of mucosa or integument are the main 
etiology of fungal infections4. In addition, severe 
COVID-19 patients have a higher risk of other 
infections due to invasive ventilation as well as usage 
of immunosuppressive medications and especially 
antibiotics2. 
Fungal infection of the central nervous system (CNS) 
is rare; however, it is associated with a poorer 
prognosis and a higher morbidity rate, compared to 
other infections of CNS5. The severity of CNS fungal 
infections mainly depends on the host immune status 
and virulence of the fungal strain. These infections have 
become remarkably common during recent years, 
especially in immunocompromised hosts6. The 
common route of fungal infection is through inhalation 
of aerosolized fungi which causes infection in the lungs. 
Generally, in immunocompromised patients, infection 
through this route spreads to other organs and results in 
hematogenous dissemination that could affect CNS5,6. 
In immunocompromised patients, the common agents 
causing CNS fungal infections are species from 
Candida, Aspergillus, and Cryptococcus genera6. 
During the COVID-19 pandemic, the incidence of 
fungal infections has increased significantly. It is 
noteworthy that the most common agents responsible 
for these fungal infections are from Aspergillus and 
Candida genera7. Candida species are the most isolated 
fungi responsible for invasive infection of 
extrapulmonary sites in COVID-19 patients2, 7, 8. Due to 
the haematological dissemination of Candida species, 
they commonly form abscesses in different areas of the 
brain. Consequently, meningoencephalitis occurs in the 
early stages, and by the progress of the infection, the 
late stages result in cerebral infarction and major 
complications5. 
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As mentioned above, in addition to the direct effects 
of COVID-19 on the immune system, different 
medical procedures could predispose COVID-19 
patients to opportunistic fungal infections in different 
sites, such as CNS6. Due to different clinical 
manifestations of COVID-19, fungal co-infections 
were not identified in many cases. Moreover, due to 
inadequate sampling and empirical therapy for these 
infections, the clinicians face many challenges during 
the treatment of COVID-19 and fungal co-
infections7,16. Overall, the fungal infections of CNS 
are rare; however, they are one of the major concerns 
due to the higher chance of occurrence in such 
vulnerable patients. Therefore, an early diagnosis and 
usage of proper medical procedures are essential for 
the prevention of the dissemination of fungal 
infections and the reduction of their high mortality 
rates. 
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Table 1: Studies that reported extrapulmonary candidiasis in COVID-19 patients. 
Study  Country  Site of infection  Mortality   Common 
species 
Salehi et al.2 Iran  Oropharyngeal 
candidiasis 
 
NM  C. albicans  
Agrifoglio et al.9 Spain  Disseminated 
candidiasis  
 
40% C. albicans 
Seitz et al.10 Germany  Disseminated 
candidiasis  
 
0% * C. glabrata 
Cataldo et al.11 Italy  Disseminated 
candidiasis  
 
NM  C. parapsilosis 
Hughes et al.12  United Kingdom Disseminated 
candidiasis  
 
NM C. albicans 
Pemán et al.13 Spain  Disseminated 
candidiasis  
 
11% C. albicans  













Rawson et al.15 United Kingdom Disseminated 
candidiasis 
NM C. albicans 
NM: not mentioned  
*: case report study 
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